Notably, IL‐1β has been demonstrated to mitigate the inflammation in septic lung injury[26a] and ameliorate pulmonary ischemia‐reperfusion injury in clinical settings.[47] Also, IL‐1β shows promise in preventing sepsis‐induced lung vascular injury in acute respiratory distress syndrome.[48] Several monoclonal antibody products targeting IL‐1β have already entered clinical trials for the treatment of inflammatory diseases[49] and cancer immunotherapy.[50] Thus, targeting IL‐1β during the perioperative period emerges as a promising approach to improve long‐term survival after cancer surgery. This evidence concerns the gene IL1B and Sepsis.